Terapi Antikoagulan pada Pasien COVID-19

Oleh :

Audric Albertus

Pemberian terapi antikoagulan pada pasien COVID-19 didasari pada laporan komplikasi dan kejadian tromboemboli. Pada awal pandemi, pemberian antikoagulan secara terapetik maupun profilaksis dipercaya memiliki tempat pada tata laksana COVID-19.

Namun, WHO living guideline tahun 2022 sudah tidak memasukan antikoagulan ke dalam pedoman penatalaksanaan COVID-19. Panduan ini akan terus diperbarui jika bukti baru yang memadai menjamin penggunaannya.[1]

Sebelumnya, koagulopati dan kasus komplikasi stroke telah ditemukan pada infeksi influenza Spanyol pada pandemi tahun 1918 dan outbreak SARS-CoV tahun 2004. Pada infeksi virus lainnya, seperti HIV/AIDS, demam dengue, penyakit virus Ebola, juga dilaporkan memiliki komplikasi trombosis. Sama halnya dengan penyakit virus lainnya, infeksi SARS-CoV-2 juga ditemukan dapat meningkatkan risiko terjadinya trombosis. [2,3]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. World Health Organization. Therapeutics and COVID-19 Living Guideline. WHO. 2022 September. https://apps.who.int/iris/bitstream/handle/10665/351006/WHO-2019-nCoV-therapeutics-2022.1-eng.pdf
2. Komiyama M, Hasegawa K. Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness. Eur Cardiol Rev. 2020;15:e58.
3. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54–67.
4. Klok FA, Kruip MJHA, Meer NJM van der, Arbous MS, Gommers DAMPJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191. 2020;145–7.
5. The Lancet Haematology. COVID-19 coagulopathy: an evolving story. Lancet Haematol. 2020;7(6):e425.
6. Tang N, Bai H, Chen X, Gong J, Li D, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.
7. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(1):122–4.
8. Lu Y-F, Pan L-Y, Wu Zhang W. A Meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. International Journal of Infectious Disease.2020;10034 – 41.
9. Hajra A, Mathai SV, Ball S, Bandyopadhyay D, Veyseh M , et al. Management of thrombotic complications in COVID-19: An Update. Drugs. 2020 Aug 16: 1-10
10. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.
11. Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, et al. Venous thromboembolism in the ICU: Main characteristics, diagnosis and thromboprophylaxis. Crit Care. 2015;19(1):1–9.
12. Dutt T, Simcox D, Downey C, McLenaghan D, King C, et al. Thromboprophylaxis in COVID-19: Anti-FXa - The missing factor? Am J Respir Crit Care Med. 2020;202(3):455–7.
13. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;(March):1023–6.
14. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest. 2020;158(3):1143–63.
15. Kementerian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Vol. 5, Kementrian Kesehatan RI. 2020. 1–214 hal.
16. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, et al. Pedoman Tatalaksana COVID-19. 2020. 1–101 hal